|
2026 Journal Article Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTIONLuong, Suzanna, Wang, William J., McKillen, Ben, Moy, Naomi, Do, Anh and Holtmann, Gerald (2026). Su1114 ACUTE EFFECTS OF BOTULINUM TOXIN ON THE DISTENSIBILITY OF THE LES IN PATIENTS WTIH SUSPECTED ACHALASIA AND ESOPHAGEAL OUTLET OBSTRUCTION. Gastrointestinal Endoscopy, 103 (5), S-723. doi: 10.1016/s0016-5107(26)01930-9 |
|
2026 Journal Article Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTIONFairlie, Thomas, Celine, Patricia, Shah, Ayesha, Lim, Yenkai, Morrison, Mark and Holtmann, Gerald (2026). Su1302 IN VITRO EFFECTS OF RIFAXIMIN ON THE DUODENAL MUCOSA ASSOCIATED MICROBIOTA CULTURED FROM PATIENTS WITH OVERLAPPING DISORDERS OF GUT-BRAIN INTERACTION. Gastroenterology, 170 (6), S-2457. doi: 10.1016/s0016-5085(26)05814-2 |
|
2026 Journal Article Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( <scp>SIBO</scp> )Shah, Ayesha, Holtmann, Gerald and Gibson, Peter R. (2026). Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth ( SIBO ). JGH Open, 10 (5) e70419. doi: 10.1002/jgh3.70419 |
|
2026 Journal Article Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEWWilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Gastrointestinal Endoscopy, 103 (5), S-2343. doi: 10.1016/s0016-5107(26)05474-x |
|
2026 Journal Article Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEWWilmes, Sophie, Holtmann, Gerald, Shah, Ayesha and Moy, Naomi (2026). Sa1003 TRUST OF PATIENTS AND CONSUMERS IN AI-SUPPORTED CLINICAL DECISION MAKING: RESULTS FROM AN AI-SUPPORTED SYSTEMATIC REVIEW. Gastroenterology, 170 (6), S-2343. doi: 10.1016/s0016-5085(26)05543-5 |
|
2026 Journal Article Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKSGonsalves, Nirmala, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Ravikumar, Pranali, Dye, Andrew, Malone, Amanda and Kowalski, Mark M. (2026). Tu1102 SINGLE ADMINISTRATION OF EP-104GI IN RESOLVE, A PHASE 1B/2 TRIAL IN EOSINOPHILIC ESOPHAGITIS, IMPROVES ENDOSCOPIC FEATURES OF INFLAMMATION AND FIBROSIS OVER 36 WEEKS. Gastrointestinal Endoscopy, 103 (5), S-817. doi: 10.1016/s0016-5107(26)02133-4 |
|
2026 Journal Article 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIALMa, Christopher, Nguyen, Nam Q., Ko, Hin Hin, Ho, Vincent, Afif, Waqqas, Holtmann, Gerald J., Dellon, Evan S., Dobek, Christine, Dye, Andrew, Kowalski, Mark M. and Malone, Amanda (2026). 400 SINGLE ADMINISTRATION OF ESCALATING DOSES OF EP-104GI LEADS TO PERSISTENT IMPROVEMENTS IN HISTOLOGICAL FEATURES OF EOSINOPHILIC ESOPHAGITIS OVER 36 WEEKS IN RESOLVE, A PHASE 1B/2 DOSE ESCALATION AND OPTIMIZATION TRIAL. Gastroenterology, 170 (6), S-627. doi: 10.1016/s0016-5085(26)01797-x |
|
2026 Journal Article Ready for Prime Time? Breath Testing to Diagnose Intestinal Dysbiosis and Guide Management in Patients With Functional Defecation DisordersShah, Ayesha and Holtmann, Gerald (2026). Ready for Prime Time? Breath Testing to Diagnose Intestinal Dysbiosis and Guide Management in Patients With Functional Defecation Disorders. Neurogastroenterology and Motility, 38 (4) e70275. doi: 10.1111/nmo.70275 |
|
2026 Journal Article Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trialLong, Millie, Allegretti, Jessica R, Danese, Silvio, Germinaro, Matthew, Baker, Thomas, Alvarez, Yelina, Kavalam, Mary, Han, Chenglong, Jörgens, Silke, Jiang, Lingjing, Zhang, Hongyan, Hisamatsu, Tadakazu, Rubin, David T, Peyrin-Biroulet, Laurent, Abu-Farsakh, Niazy, Al-Rousan, Lawrence, An, Ping, Argollo, Marjorie, Arguelles Arias, Federico, Augustyn, Monika, Baert, Filip, Balderramo, Domingo, Banerjee, Rupa, Baum, Curtis, Bermudez Villegas, Emilio, Blanco, Antonio, Bortlik, Martin, Bouhnik, Yoram, Soledad Brunatto, Luciana ... Zou, Duowu (2026). Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology and Hepatology, 11 (4), 284-298. doi: 10.1016/S2468-1253(25)00322-X |
|
2026 Journal Article Gastrointestinal symptoms and systemic comorbidities in patients with POTS : a systematic review and meta‐analysisKulin, Dmitrii, Shah, Ayesha, Fairlie, Thomas, Staller, Kyle, Nurko, Samuel, Keefer, Laurie, Aziz, Qasim, Drossman, Douglas A., Jones, Michael P. and Holtmann, Gerald (2026). Gastrointestinal symptoms and systemic comorbidities in patients with POTS : a systematic review and meta‐analysis. Neurogastroenterology & Motility, 38 (4) e70305, 1-13. doi: 10.1111/nmo.70305 |
|
2026 Journal Article Exercise capacity and neuromuscular fitness in people with disorders of gut-brain interaction (DGBI)Bell, Katherine, Kulin, Dmitrii, McAllister, Sarah, Cougan, Rhiannon, O'Brien, Jake, West, Dale, Shah, Ayesha, Koloski, Natasha, Nicol, Jennifer, Holtmann, Gerald and Coombes, Jeff (2026). Exercise capacity and neuromuscular fitness in people with disorders of gut-brain interaction (DGBI). Journal of Clinical Exercise Physiology, 15 (s2), 225-225. doi: 10.31189/2165-7629-15-s2.225 |
|
2026 Journal Article symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interactionColomier, Esther, Jones, Michael P., Holvoet, Lieselot, Van den Houte, Karen, Van de Bruaene, Cedric, Broeders, Bert, Bai, Tao, Liu, Jinsong, Melchior, Chloé, Gourcerol, Guillaume, Chuah, Kee-Huat, Hui, Khoo Xin, Mahadeva, Sanjiv, Ho Siah, Kewin Tien, Lipták, Peter, Banovcin, Peter, Holtmann, Gerald, Koloski, Natasha, Carabotti, Marilia, Annibale, Bruno, Suzuki, Hidekazu, Sano, Masaya, Ueda, Takashi, Hajihashemi, Parisa, Shahoon, Hassan, Adibi, Payman, Simrén, Magnus, Gwee, Kok-Ann, Tack, Jan and Carbone, Florencia (2026). symptom patterns outside the rome iv consensus in eastern and western patients with a disorder of gut-brain interaction. American Journal of Gastroenterology, Publish Ahead of Print 10.14309/ajg.0000000000003996. doi: 10.14309/ajg.0000000000003996 |
|
2026 Journal Article Measuring lifetime alcohol exposure: a scoping review and implications for translational research and alcohol‐related harmPalmer, Andrew J., Connor, Jason P., Holtmann, Gerald, Saunders, John B., Rice, Katie, Yeo, Jeremy, Huang, Andrea and Clark, Paul J. (2026). Measuring lifetime alcohol exposure: a scoping review and implications for translational research and alcohol‐related harm. Addiction, 121 (3), 472-487. doi: 10.1111/add.70208 |
|
2026 Conference Publication WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCOREIdris, Iskandar, Benes, Marek, Haluzik, Martin, Byrne, James, Munro, Lynne, Frydenberg, Harry, Teare, Julian, Ruban, Aruchuna, Mason, John, Holtmann, Gerald, Mcmaster, Jess and Ryder, Robert (2026). WEIGHT LOSS OUTCOMES IN RESPONSE TO TREATMENT WITH DUODENAL-JEJUNAL BYPASS LINER ARE THE SAME REGARDLESS OF DIABETES SEVERITY ASSESSED USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE. THOUSAND OAKS: SAGE PUBLICATIONS INC. |
|
2026 Journal Article Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forwardGrady, John, Johnson, Kevin M., Kellermayer, Richard, Winter, Harland S., Tabibian, James H., Buness, Cynthia W., Fischer, Ryan, Shah, Ayesha, Dulai, Parambir S., Rangnekar, Amol S., Alrabadi, Leina, Shah, Shamita B., Holtmann, Gerald, Räisänen, Laura, Lewindon, Peter and Ali, Ahmad H. (2026). Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forward. Expert Review of Gastroenterology & Hepatology, 20 (3) 17474124.2026.2635420, 233-246. doi: 10.1080/17474124.2026.2635420 |
|
2026 Journal Article Disorders of gut–brain interaction (DGBI) symptoms and response to peroral endoscopic myotomy in patients with achalasiaJacob, Ronen Ben, Fairlie, Thomas, Talley, Nicholas J., Taylor, Andrew, Frankel, Adam, Smithers, B. Mark, Pandolfino, John E., Jones, Michael P., Hourigan, Luke F., Shah, Ayesha and Holtmann, Gerald (2026). Disorders of gut–brain interaction (DGBI) symptoms and response to peroral endoscopic myotomy in patients with achalasia. Neurogastroenterology and Motility, 38 (1) e70223, 1-11. doi: 10.1111/nmo.70223 |
|
2025 Journal Article Evidence for brain‐to‐gut and gut‐to‐brain pathways in primary care patients with disorders of gut‐brain interaction, inflammatory bowel disease and gastroesophageal reflux diseaseKoloski, N. A., Jones, M. P., Shah, A., Holtmann, G. and Talley, N. J. (2025). Evidence for brain‐to‐gut and gut‐to‐brain pathways in primary care patients with disorders of gut‐brain interaction, inflammatory bowel disease and gastroesophageal reflux disease. Neurogastroenterology and Motility, 37 (12) e70117, e70117. doi: 10.1111/nmo.70117 |
|
2025 Journal Article Key recommendations to improve equity and access in colorectal cancer screening for rural and remote communities. a grounded theory studyMarinucci, Nicole, Koloski, Natasha, Baker, Kate, Moy, Naomi and Holtmann, Gerald (2025). Key recommendations to improve equity and access in colorectal cancer screening for rural and remote communities. a grounded theory study. Australian and New Zealand Journal of Public Health, 49 (6) 100295, 100295. doi: 10.1016/j.anzjph.2025.100295 |
|
2025 Conference Publication Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic EsophagitisMalone, Amanda, Helliwell, James, Kowalski, Mark, Nguyen, Nam, Ko, Hin Hin, Holtmann, Gerald, Afif, Waqqas, Bredenoord, Albert J., Dobek, Christine, Ravikumar, Pranali, Peck, Vik and Dellon, Evan S. (2025). Results From Dose Escalation Cohorts 1-6 of RESOLVE, an Ongoing Phase 1b/2a Study of EP-104GI (Long-Acting Fluticasone Propionate Injectable Suspension) for Eosinophilic Esophagitis. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.14309/01.ajg.0001131024.83021.f2 |
|
2025 Journal Article Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel DiseasesMoniruzzaman, Md, Shah, Ayesha, Fairlie, Thomas, Keely, Simon, Burns, Grace L., Talley, Nicholas and Holtmann, Gerald (2025). Immune Activation in Primary Sclerosing Cholangitis: A Systematic Review and Comparative Analysis With Inflammatory Bowel Diseases. United European Gastroenterology Journal, 13 (9) ueg2.70115, 1-14. doi: 10.1002/ueg2.70115 |
